Coloplast divests skin care biz
By HME News Staff
Updated 10:06 AM CST, Thu December 5, 2024
MINNEAPOLIS – Coloplast has divested its core Skin Care business to focus on its Advanced Wound Care business. Revenue from the core Skin Care business amounted to around DKK 400 million in FY 2023/24, with an operating profitability level significantly below the group EBIT margin. Coloplast’s FY 2024/25 financial guidance of organic revenue growth of 8% to 9% and an EBIT margin before special items of around 28% is unchanged and already includes the divestment. This simplification of the portfolio will benefit the operating profitability of Advanced Wound Care and accounts for the majority of the around 30 basis points positive impact on the group EBIT margin as highlighted in the FY 2023/24 earnings release. The transaction was completed on Dec. 3. Specific terms of the transaction have not been disclosed.
Comments